tradingkey.logo

Taysha Gene Therapies Inc <TSHA.OQ> expected to post a loss of 8 cents a share - Earnings Preview

ReutersFeb 24, 2025 1:34 PM
  • Taysha Gene Therapies Inc TSHA.OQ TSHA.O is expected to show a fall in quarterly revenue when it reports results on February 26 for the period ending December 31 2024

  • The Dallas Texas-based company is expected to report a 35.9% decrease in revenue to $2.309 million from $3.6 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.

  • ​LSEG's mean analyst estimate for Taysha Gene Therapies Inc is for a loss of 8 cents per share.

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Taysha Gene Therapies Inc is $7.00​, above​ its last closing price of $1.61. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING

STARMINESMARTESTIMATE®

LSEG IBES ESTIMATE

ACTUAL

BEAT, MET, MISSED

SURPRISE %

Sep. 30 2024

-0.10

-0.09

-0.10

Missed

-8

Jun. 30 2024

-0.16

-0.16

-0.09

Beat

45.3

Mar. 31 2024

-0.12

-0.11

-0.10

Beat

8.6​

Dec. 31 2023

-0.11

0.92

Beat

936.4

​​Sep. 30 2023

-0.19

-0.17

-0.13

Beat

24.7

Jun. 30 2023

-0.31

-0.31

-0.38

Missed

-22.1​

Mar. 31 2023

-0.36

-0.35

-0.28

Beat

20.9

Dec. 31 2022

-0.42

-0.33

-0.34

Missed

-3.3

This summary was machine generated February 24 at 13:34 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI